CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 2, 2023-- Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that it will host a live webcast on Thursday, February 16, 2023 at 8:00 a.m.

Robust pipeline provides potential for long-term value creation, establishing Sage as a leader in brain health Rolling New Drug Application (NDA) submission for zuranolone in MDD and PPD complete, with potential for PDUFA date as early as the third quarter of 2023 if priority review is received and

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 3, 2023-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will present at the 41 st Annual J.P. Morgan Healthcare Conference on Tuesday, January

Zuranolone is being evaluated as a short course, rapid-acting, oral medication for major depressive disorder (MDD) and postpartum depression (PPD) CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 6, 2022-- Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc.

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 23, 2022-- Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will present at the Piper Sandler 34 th Annual Healthcare Conference on Thursday,

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 22, 2022-- Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today announced that the companies will host a joint investor webcast to discuss the planned commercialization approach and opportunity for their investigational product,

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 9, 2022-- Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will present at the Stifel 2022 Healthcare Conference on Wednesday, November 16, 2022 ,

Completion of rolling NDA submission for zuranolone in MDD and PPD on track for December 2022 Presented additional data across pipeline programs at key medical congresses including data on zuranolone as an investigational oral, once-daily, 14-day treatment for MDD and PPD Company appoints Laura

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 1, 2022-- Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced the appointment of Laura Gault , MD, Ph.D. as Chief Medical Officer. In her new role, Dr.

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 25, 2022-- Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that it will host a live webcast on Tuesday, November 8, 2022 at 8:00 a.m.